Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ALPN-202 |
Synonyms | |
Therapy Description |
ALPN-202 is a fusion protein consisting of the N-terminal Ig variable-like (IgV) domain of CD80 fused to an immunoglobulin G1 (IgG1) Fc fragment that inhibits programmed cell death-1 ligand 1 (PD-L1; CD274) and CTL-associated antigen 4 (CTLA4) signaling and activates PD-L1-dependent CD28 signaling, which potentially leads to immune checkpoint inhibition and increased antitumor immune response (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2547-2547). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALPN-202 | ALPN 202|ALPN202|CD80 vIgD-Fc Fusion Protein ALPN-202 | CTLA4 Inhibitor 4 Immune Checkpoint Inhibitor 148 PD-L1 Inhibitor 13 | ALPN-202 is a fusion protein consisting of the N-terminal Ig variable-like (IgV) domain of CD80 fused to an immunoglobulin G1 (IgG1) Fc fragment that inhibits programmed cell death-1 ligand 1 (PD-L1; CD274) and CTL-associated antigen 4 (CTLA4) signaling and activates PD-L1-dependent CD28 signaling, which potentially leads to immune checkpoint inhibition and increased antitumor immune response (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 2547-2547). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04186637 | Phase I | ALPN-202 | An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1) | Terminated | USA | AUS | 0 |